UC San Diego Health News
UC San Diego Health, the region’s only academic medical center, delivers world-class care and translates groundbreaking research into promising new treatments for patients.
The Latest
Patient First in Region to Receive New Treatment for Advanced Prostate Cancer (external site)
UC San Diego Health is the first hospital system in the region to offer a novel treatment option for patients with prostate cancer that has spread throughout the body and has not responded to other therapeutics.
A Rhythmic Small Intestinal Microbiome Prevents Obesity and Type 2 Diabetes (external site)
Researchers used mouse models to explore how diet and feeding patterns affect the rodents’ intestinal microbes, and obesity and type 2 diabetes.
New Radiation Therapy Delays Brain Cancer Regrowth, Protects Healthy Tissue (external site)
Novel therapy option shown to extend the lifespan and improve quality of life for certain patients
UC San Diego Health Recognized by Vizient (external site)
UC San Diego Health has been recognized as a top performer in the 2022 Quality Leadership Ranking by Vizient, Inc. This is the fourth consecutive year that UC San Diego Health has been ranked among the top ten academic health systems in the United States.
Mathematical Model Helps Predict Anal Cancer Risk in Persons with HIV Infection (external site)
Researchers are using a new model to help predict anal cancer risk in persons with HIV infection.
In the Media
What Happens to Testosterone When You Don’t Get Enough Sleep? We Have Some New Answers
Men's Health, August 10
How the top Magnet hospitals score on nurse communication
Becker's Hospital Review, August 12
AI decision support is scaling-up fast — can the evidence keep up?
Nature, August 13
UC San Diego Health, West Health launch $40M accelerator for ‘tech-forward’ coordinated care
Fierce Healthcare, August 12
Stay in the Know
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
Thank you!
You have been successfully subscribed to the UC San Diego Today Newsletter.